Transluminally implantable cardiac valves configured for use in cardiac valve replacement and/or cardiac valve exclusion that are capable of percutaneous delivery on low-profile catheters having 15 French size or less. The implantable cardiac valves are fabricated of from a unitary metal material to form a lattice frame support having a main body portion and valve leaflet portion, and a plurality of elongate biasing arm members. A polymer coating or covering is disposed on the valve leaflet portion and the elongate biasing arm members and subtends space between adjacent pairs of elongate biasing arm members to form valve leaflet portions in which the elongate biasing arms and the polymer coating operate to share a mechanical load thereupon.

Transluminally implantable cardiac valves configured for use in cardiac valve replacement and/or cardiac valve exclusion that are capable of percutaneous delivery on low-profile catheters having 15 French size or less. The implantable cardiac valves are fabricated of from a unitary metal material to form a lattice frame support having a main body portion and valve leaflet portion, and a plurality of elongate biasing arm members. A polymer coating or covering is disposed on the valve leaflet portion and the elongate biasing arm members and subtends space between adjacent pairs of elongate biasing arm members to form valve leaflet portions in which the elongate biasing arms and the polymer coating operate to share a mechanical load thereupon.

Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (IαI). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided.

Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (IαI). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided.

Biodegradable magnesium alloy implantable medical devices are protected to delay onset of corrosion, and thus biodegradability, or to corrode more uniformly. The protection allows for extended effective use of the devices while maintaining biodegradability. Examples of protective coatings include conversion coatings that at least partially remove exposed second phases from a surface of the magnesium alloy and coatings that provide a barrier between water and the surface of the magnesium alloy.

Biodegradable magnesium alloy implantable medical devices are protected to delay onset of corrosion, and thus biodegradability, or to corrode more uniformly. The protection allows for extended effective use of the devices while maintaining biodegradability. Examples of protective coatings include conversion coatings that at least partially remove exposed second phases from a surface of the magnesium alloy and coatings that provide a barrier between water and the surface of the magnesium alloy.

An intraluminal endoprosthesis has a biodegradable metallic supporting structure and a biodegradable sleeve surrounding the supporting structure. The sleeve includes fibres applied to the outer side of the supporting structure. The sleeve can be formed from fibres that each have a polymer core and a hydrogel casing. The sleeve can the sleeve be formed from a fibre mixture of polymer fibres and hydrogel fibres.

An intraluminal endoprosthesis has a biodegradable metallic supporting structure and a biodegradable sleeve surrounding the supporting structure. The sleeve includes fibres applied to the outer side of the supporting structure. The sleeve can be formed from fibres that each have a polymer core and a hydrogel casing. The sleeve can the sleeve be formed from a fibre mixture of polymer fibres and hydrogel fibres.

An intraluminal endoprosthesis has a biodegradable metallic supporting structure and a biodegradable sleeve surrounding the supporting structure. The sleeve includes fibres applied to the outer side of the supporting structure. The sleeve can be formed from fibres that each have a polymer core and a hydrogel casing. The sleeve can the sleeve be formed from a fibre mixture of polymer fibres and hydrogel fibres.

An object is to provide a zwitterionic compound having an excellent protein adsorption inhibitory effect. The zwitterionic compound is a polymer comprising a unit represented by the following formula (1):

##STR00001##

wherein R.sup.1 is a hydrogen atom or a methyl group, R.sup.2 is OH or O.sup.−, X.sup.1 is —O— or —N(Q.sup.1)-, Q.sup.1 is a hydrogen atom or a C.sub.1-6 alkyl group, m is an integer of 1 to 12, and n is an integer of 1 to 4.